Novavax, Inc.

Novavax, Inc. develops and manufactures protein-based vaccines, including its COVID-19 vaccine and other candidates in its pipeline. The company’s vaccine development process inherently involves animal testing as a required component of preclinical safety and efficacy studies. Regulatory submissions for its products, such as Investigational New Drug (IND) applications, include results from animal studies assessing toxicology and pharmacodynamics, as disclosed in its public filings. This testing is conducted to comply with U.S. Food and Drug Administration and international regulatory requirements for vaccine authorization.

The company’s platform technology and adjuvant system are evaluated in animal models during the research stage. For instance, development of its COVID-19 vaccine candidate included preclinical trials in animal subjects to assess immunogenicity and safety profiles prior to human clinical trials. As a biotechnology firm whose core business is bringing novel vaccines to market, Novavax engages in animal testing as a standard, non-optional element of its product development and regulatory compliance pathway.